Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R PEN.
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R PEN.
HUMULIN 70/30 vs HUMULIN R PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin replacement therapy. Human insulin is a recombinant DNA-derived polypeptide hormone that regulates glucose metabolism. Insulin binds to the insulin receptor, activating tyrosine kinase activity, which leads to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis and lipogenesis.
Insulin is a hormone produced by the pancreas that regulates glucose metabolism. Exogenous insulin replaces endogenous insulin, binding to insulin receptors on cell surfaces, activating tyrosine kinase activity, and promoting glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and lipolysis.
Subcutaneous injection, 0.5-1.0 units/kg/day divided into two doses (before breakfast and before dinner), adjusted based on blood glucose monitoring.
Subcutaneous injection, usual starting dose 0.2 to 0.4 units/kg/day divided into two or more injections; total daily insulin requirements may range from 0.5 to 1.0 units/kg/day.
None Documented
None Documented
0.5-1 hour (free insulin); 8-12 hours (prolonged due to NPH component, reflecting duration of action).
Intravenous: plasma half-life is ~5-10 minutes (distribution) and elimination half-life ~1.5-2 hours (reflecting clearance from peripheral compartments). Subcutaneous: prolonged due to absorption rate-limited kinetics; terminal half-life ~5-10 hours.
Renal: 100% (metabolized to inactive fragments; negligible excretion of intact insulin).
Primarily renal (hepatic metabolism to inactive metabolites accounts for <20%); ~30-80% of dose excreted unchanged in urine via glomerular filtration.
Category C
Category C
Human Insulin
Human Insulin